{"public_id":"co_d846aa56a493c0b66e60a3171162cab1","status":"active","merged_into_public_id":null,"resolved_public_id":"co_d846aa56a493c0b66e60a3171162cab1","name":"trivalent inactivated intradermal vaccine (3-IIV ID)","description":"A specific seasonal influenza vaccine administered intradermally; the only vaccine not more effective than placebo in adults/elderly.","aliases":[],"types":["vaccine type"],"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":241185914,"title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis","citation_count":56,"url":"https://sah.borca.ai/papers/241185914"}],"claims":[{"public_id":"cl_ce086d6a8cc9e4cfefdb47203be80f37","text":"In adults and elderly, all seasonal influenza vaccines except trivalent inactivated intradermal (3-IIV ID) significantly reduced the risk of laboratory-confirmed influenza compared to placebo, with risk ratios ranging from 0.33 (3-IIV HD) to 0.56 (3-LAIV).","corpus_id":241185914,"url":"https://sah.borca.ai/claims/cl_ce086d6a8cc9e4cfefdb47203be80f37"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_d846aa56a493c0b66e60a3171162cab1","url":"https://sah.borca.ai/concepts/co_d846aa56a493c0b66e60a3171162cab1"}